Relay Therapeutics/RLAY

$5.96

-2.45%
-
1D1W1MYTD1YMAX

About Relay Therapeutics

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.

Ticker

RLAY

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sanjiv Patel

Employees

323

Headquarters

Cambridge, United States

RLAY Metrics

BasicAdvanced
$801.5M
Market cap
-
P/E ratio
-$2.79
EPS
1.71
Beta
-
Dividend rate
$801.5M
1.70636
$13.32
$5.95
1.18M
25.442
-35.19%
-40.18%
-36.97%
31.375
1.036
1.069
1,749.82%
-7.46%
-32.39%

What the Analysts think about RLAY

Analyst Ratings

Majority rating from 12 analysts.
Buy

Price Targets

Average projection from 11 analysts.
286.74% upside
High $33.00
Low $10.60
$5.96
Current price
$23.05
Average price target

RLAY Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,340.78% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$25.5M
1.19%
Net income
$-341.9M
420.4%
Profit margin
-1,340.78%
414.28%

RLAY Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.01%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.78
-$0.81
-$0.54
-$0.67
-
Expected
-$0.69
-$0.82
-$0.83
-$0.73
-$0.71
Surprise
12.84%
-0.69%
-35%
-8.01%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Relay Therapeutics stock?

Relay Therapeutics (RLAY) has a market cap of $801.5M as of April 20, 2024.

What is the P/E ratio for Relay Therapeutics stock?

The price to earnings (P/E) ratio for Relay Therapeutics (RLAY) stock is 0 as of April 20, 2024.

Does Relay Therapeutics stock pay dividends?

No, Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Relay Therapeutics dividend payment date?

Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders.

What is the beta indicator for Relay Therapeutics?

Relay Therapeutics (RLAY) has a beta rating of 1.71. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Relay Therapeutics stock price target?

The target price for Relay Therapeutics (RLAY) stock is $23.05, which is 286.74% above the current price of $5.96. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Relay Therapeutics stock

Buy or sell Relay Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing